Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker AQST
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Richard J. Daly Director | AQST Aquestive Therapeutics, Inc. | Buy | 26,825 | $3.55 | $95.1K Buy | Form 4 ↗ |
| Nov 10, 2026 | Richard J. Daly Director | AQST Aquestive Therapeutics, Inc. | Buy | 1,200 | $3.53 | $4,236 Buy | Form 4 ↗ |
| Oct 15, 2026 | Daniel Barber President and CEO, Director | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $4.22 | $105.6K Sale | Form 4 ↗ |
| Sep 15, 2026 | Daniel Barber President and CEO, Director | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $4.82 | $120.5K Sale | Form 4 ↗ |
| Sep 9, 2026 | Sherry Korczynski Chief Commercial Officer | AQST Aquestive Therapeutics, Inc. | Sale | 8,750 | $5.22 | $45.7K Sale | Form 4 ↗ |
| Aug 17, 2026 | Daniel Barber President and CEO, Director | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $4.29 | $107.3K Sale | Form 4 ↗ |
| Jul 16, 2026 | Daniel Barber President and CEO | AQST Aquestive Therapeutics, Inc. | Sale | 20,369 | $4.00 | $81.5K Sale | Form 4 ↗ |
| Jul 15, 2026 | Daniel Barber President and CEO | AQST Aquestive Therapeutics, Inc. | Sale | 4,631 | $4.03 | $18.7K Sale | Form 4 ↗ |
| Jun 23, 2026 | Julie Krop Director | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $5.02 | $125.5K Sale | Form 4 ↗ |
| Jun 15, 2026 | Daniel Barber President and CEO | AQST Aquestive Therapeutics, Inc. | Sale | 25,000 | $4.16 | $104.0K Sale | Form 4 ↗ |
| May 15, 2026 | Daniel Barber President and CEO | AQST Aquestive Therapeutics, Inc. | Sale | 8,257 | $4.29 | $35.4K Sale | Form 4 ↗ |
| Mar 10, 2026 | Peter E. Boyd Chief People Officer | AQST Aquestive Therapeutics, Inc. | Sale | 29,814 | $4.17 | $124.3K Sale | Form 4 ↗ |
| Mar 10, 2026 | Daniel Barber President and CEO | AQST Aquestive Therapeutics, Inc. | Sale | 180,677 | $4.17 | $753.4K Sale | Form 4 ↗ |
| Mar 10, 2026 | Lori J. Braender Chief Legal Officer | AQST Aquestive Therapeutics, Inc. | Sale | 40,102 | $4.17 | $167.2K Sale | Form 4 ↗ |
| Mar 10, 2026 | Melina Cioffi SVP, Regulatory Affairs | AQST Aquestive Therapeutics, Inc. | Sale | 25,311 | $4.17 | $105.5K Sale | Form 4 ↗ |
| Mar 10, 2026 | A. Ernest Toth Jr. Chief Financial Officer | AQST Aquestive Therapeutics, Inc. | Sale | 58,254 | $4.17 | $242.9K Sale | Form 4 ↗ |
| Mar 10, 2026 | Sherry Korczynski Chief Commercial Officer | AQST Aquestive Therapeutics, Inc. | Sale | 15,741 | $4.17 | $65.6K Sale | Form 4 ↗ |
| Mar 10, 2026 | Cassie Jung Chief Operating Officer | AQST Aquestive Therapeutics, Inc. | Sale | 45,791 | $4.17 | $190.9K Sale | Form 4 ↗ |
| Oct 15, 2025 | Cassie Jung Chief Operating Officer | AQST Aquestive Therapeutics, Inc. | Sale | 67,575 | $7.01 | $473.7K Sale | Form 4 ↗ |
| Oct 15, 2025 | Carl N. Kraus Chief Medical Officer | AQST Aquestive Therapeutics, Inc. | Sale | 20,272 | $7.00 | $141.9K Sale | Form 4 ↗ |
| Oct 15, 2025 | Peter E. Boyd See Remarks | AQST Aquestive Therapeutics, Inc. | Sale | 10,000 | $7.00 | $70.0K Sale | Form 4 ↗ |
| Sep 26, 2025 | Daniel Barber President and CEO, Director | AQST Aquestive Therapeutics, Inc. | Sale | 91,343 | $6.03 | $550.8K Sale | Form 4 ↗ |
| Sep 26, 2025 | Peter E. Boyd See Remarks | AQST Aquestive Therapeutics, Inc. | Sale | 10,000 | $6.30 | $63.0K Sale | Form 4 ↗ |
| Sep 19, 2025 | Daniel Barber President and CEO, Director | AQST Aquestive Therapeutics, Inc. | Sale | 400 | $6.00 | $2,400 Sale | Form 4 ↗ |
| Sep 5, 2025 | Peter E. Boyd See Remarks | AQST Aquestive Therapeutics, Inc. | Sale | 15,000 | $5.30 | $79.5K Sale | Form 4 ↗ |
| Sep 4, 2025 | Cassie Jung Chief Operating Officer | AQST Aquestive Therapeutics, Inc. | Sale | 62,180 | $5.00 | $310.9K Sale | Form 4 ↗ |
| Nov 26, 2024 | Cassie Jung Chief Operating Officer | AQST Aquestive Therapeutics, Inc. | Sale | 44 | $4.87 | $214 Sale | Form 4 ↗ |
27 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances